AR052544A1 - DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT - Google Patents
DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING ITInfo
- Publication number
- AR052544A1 AR052544A1 ARP050105485A ARP050105485A AR052544A1 AR 052544 A1 AR052544 A1 AR 052544A1 AR P050105485 A ARP050105485 A AR P050105485A AR P050105485 A ARP050105485 A AR P050105485A AR 052544 A1 AR052544 A1 AR 052544A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxy
- heteroaryl
- independently
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso de los compuestos de la formula general A para el tratamiento de diversas enfermedades, así como a la preparacion de compuestos de la formula general A. Reivindicacion 1: Derivado de quinolina de la formula general A en donde A está seleccionado del grupo que comprende -arilo C6-12, - heteroarilo C5-18, -cicloalquilo C3-12 y -heterocicloalquilo C3-12; R1 y R2 son iguales o diferentes y están seleccionados, una o varias veces independientemente entre sí, del grupo que comprende H, hidroxi, halogeno, nitro, ciano, -alquilo C1-6, -hidroxi-alquilo C1-4, - alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, heterocicloalquilo C3-12, -arilo C6-12, -heteroarilo C5-18, -alcoxi C1-6, -alcoxi c1-6- alcoxi c1-6, -alcoxi C1-6-alquilo C1-6, -alcoxi C1-6-alcoxi C1-6-alquilo C1-6, -(CH2)n-arilo C6-12, -(CH2)n-heteroarilo C5-18, -(CH2)n- cicloalquilo C3-10, -(CH2)n-heterocicloalquilo C3-12, -fenilen-(CH2)p-R6, -(CH2)pPO3(R6)2, -(CH2)p-NR4S(O)R5, -(CH2)p-NR4S(O)2R5, -(CH2)p- NR4CONR5R6, -(CH2)p-NR4COOR5, -(CH2)p-NR4C(NH)NR5R6, -(CH2)p-NR4CSNR5R6, -(CH2)p-NR4S(O)NR5R6, -(CH2)p- NR4S(O)23NR5R6, -(CH2)p-COR5, -(CH2)p-CSR5, -(CH2)p-S(O)R5, -(CH2)p-S(O)(NH)R5, -(CH2)p-S(O)2R5, -(CH2)p-S(O)2NR5R6, -(CH2)p-SO2OR5, -(CH2)p- CO2R5, -(CH2)p-CONR5R6, -(CH2)p-CSNR5R6, -OR5, -(CH2)p-SR5 y -CR5(OH)-R6, en donde -alquilo C1-6, -alquenilo C2-6, -alquinilo C2-6, -cicloalquilo C3-10, -heterocicloalquilo C3-12, -arilo C6-12, -heteroarilo C5-18 y/o -alcoxi c1-6 no están sustituidos o están sustituidos, una o varias veces independientemente entre sí, con hidroxi, halogeno, nitro, ciano, fenilo, -NR5R6, alquilo y/u -OR5, en donde la estructura del C del -cicloalquilo C3-10 y del -alquilo C1-10 puede contener, una o varias veces independientemente entre sí, átomos de N, O, S y/o grupos C=O y/o uno o varios enlaces dobles, y/o R1 y R2 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o -NR4; X, Y, Z, son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende -CR3=, -CR3R4-, -C(O)-, -N=, -S-, -O-, -NR3-, -S(O)2-, -S(O)- y -S(O)NH-, y se hallan entre X, Y y Z enlaces simples o dobles; R3 es H, -alquilo C1-10 o -alcanoílo C1-10; R4 es H o -alquilo C1-10; R5 y R6 son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende H, -alquilo C1-10, -alquenilo C2-10, - alquinilo C2-10, -alcoxi C1-6, -cicloalquilo C3-10, -heterocicloalquilo C3-12, -arilo C6-12 y -heteroarilo C5-18, en donde -alquilo C1-10, -alquenilo C2-10, -alquinilo C2-10, -alcoxi C1-6, -cicloalquilo C3-10, - heterocicloalquilo C3-12, -arilo C6- 12 y/o -heteroarilo C5-18 no están sustituidos o están mono- o polisustituidos independientemente entre sí con hidroxi, halogeno, ciano, nitro, -OR7, -NR7R8, -C(O)NR7R8, -C(O)OR7 y/o -alquilo C1-6, en donde -alquilo c1-6 no está sustituido o está mono- o polisustituido independientemente entre sí con halogeno, hidroxi, ciano, -NR7R8, -OR7 y/o fenilo; y/o R5 y R6 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o NR4; R7, R8 son iguales o diferentes y están seleccionados, independientemente entre sí, del grupo que comprende H, -alquilo c1-4, -arilo C6-12 y -heteroarilo C5-18, en donde alquilo, arilo, heteroarilo no está sustituido o está sustituido, una o varias veces independientemente entre sí, con y/o alcoxi, o R7 y R8 forman opcionalmente entre sí un puente de 3-10 unidades de metileno, en donde hasta dos unidades de metileno se reemplazan opcionalmente con O, S y/o - NR4;m', mö = independientemente entre sí 0-4; n = 1-6, p = 0-6, así como sus N-oxidos, solvatos, hidratos, estereoisomeros, diastereoisomeros, enantiomeros y sales con la condicion de que, cuando X, Y, Z significan independientemente entre sí 1, 2 o 3 N, 1) el esqueleto del subgrupo X-Y-Z no sea N- CH-N, CH-N-N o -N-N-N y 2) X no sea NH cuando Y y Z son al mismo tiempo CH.Use of the compounds of the general formula A for the treatment of various diseases, as well as the preparation of compounds of the general formula A. Claim 1: Quinoline derivative of the general formula A wherein A is selected from the group comprising - C6-12 aryl, - C5-18 heteroaryl, - C3-12 cycloalkyl and - C3-12 heterocycloalkyl; R1 and R2 are the same or different and are selected, once or several times independently from each other, from the group comprising H, hydroxy, halogen, nitro, cyano, -C 1-6 alkyl, -hydroxy-C 1-4 alkyl, - C 2 alkenyl -6, -C2-6alkynyl, -C3-10cycloalkyl, C3-12 heterocycloalkyl, -C6-12 -aryl, -C5-18 heteroaryl, -C1-6 alkoxy, -C1-6 alkoxy-C1-6 alkoxy, - C1-6 alkoxy-C1-6 alkyl, -C 1-6 alkoxy-C1-6 alkoxy-C1-6 alkyl, - (CH2) n-aryl C6-12, - (CH2) n-heteroaryl C5-18, - ( CH2) n- C3-10 cycloalkyl, - (CH2) n-heterocycloalkyl C3-12, -phenylene- (CH2) p-R6, - (CH2) pPO3 (R6) 2, - (CH2) p-NR4S (O) R5, - (CH2) p-NR4S (O) 2R5, - (CH2) p- NR4CONR5R6, - (CH2) p-NR4COOR5, - (CH2) p-NR4C (NH) NR5R6, - (CH2) p-NR4CSNR5R6, - (CH2) p-NR4S (O) NR5R6, - (CH2) p- NR4S (O) 23NR5R6, - (CH2) p-COR5, - (CH2) p-CSR5, - (CH2) pS (O) R5, - (CH2) pS (O) (NH) R5, - (CH2) pS (O) 2R5, - (CH2) pS (O) 2NR5R6, - (CH2) p-SO2OR5, - (CH2) p- CO2R5, - (CH2) p-CONR5R6, - (CH2) p-CSNR5R6, -OR5, - (CH2) p-SR5 and -CR5 (OH) -R6, where -C1-6 alkyl, -C2-6 alkenyl, -alkynyl C2-6, -C3-10 cycloalkyl, -C3-12 heterocycloalkyl, -C6-12 -aryl, -C5-18 heteroaryl and / or -C1-6 alkoxy are not substituted or substituted, once or several times independently of each other, with hydroxy, halogen , nitro, cyano, phenyl, -NR5R6, alkyl and / or -OR5, wherein the C structure of the C3-10 cycloalkyl and the C1-10 alkyl can contain, once or several times independently of each other, N atoms , O, S and / or groups C = O and / or one or several double bonds, and / or R1 and R2 optionally form a bridge of 3-10 methylene units, where up to two methylene units are optionally replaced with O, S and / or -NR4; X, Y, Z, are the same or different and are independently selected from the group comprising -CR3 =, -CR3R4-, -C (O) -, -N =, -S-, -O-, - NR3-, -S (O) 2-, -S (O) - and -S (O) NH-, and single or double bonds are between X, Y and Z; R3 is H, -C1-10 alkyl or -C1-10 alkanoyl; R4 is H or -C1-10 alkyl; R5 and R6 are the same or different and are independently selected from the group comprising H, -C1-10 alkyl, -C2-10 alkenyl, -C2-10 alkynyl, -C1-6 alkoxy, -C3-10 -cycloalkyl , -C3-12 heterocycloalkyl, -C6-12 -aryl and -C5-18 heteroaryl, wherein -C1-10 alkyl, -C2-10 alkenyl, -C2-10 alkynyl, -C1-6 alkoxy, -C3-10 -cycloalkyl , - C3-12 heterocycloalkyl, C6-12 -aryl and / or -C5-18 heteroaryl are not substituted or are mono- or polysubstituted independently of each other with hydroxy, halogen, cyano, nitro, -OR7, -NR7R8, -C ( O) NR7R8, -C (O) OR7 and / or -C1-6 alkyl, wherein -C1-6 alkyl is not substituted or is mono- or polysubstituted independently of one another with halogen, hydroxy, cyano, -NR7R8, -OR7 and / or phenyl; and / or R5 and R6 optionally form a bridge of 3-10 methylene units with each other, where up to two methylene units are optionally replaced with O, S and / or NR4; R7, R8 are the same or different and are independently selected from the group comprising H, -C1-4 alkyl, -C6-12 alkyl and -C5-18 heteroaryl, wherein alkyl, aryl, heteroaryl is unsubstituted or is substituted, once or several times independently of each other, with and / or alkoxy, or R7 and R8 optionally form a bridge of 3-10 methylene units, where up to two methylene units are optionally replaced with O, S and / o - NR4; m ', mö = independently from each other 0-4; n = 1-6, p = 0-6, as well as their N-oxides, solvates, hydrates, stereoisomers, diastereoisomers, enantiomers and salts with the proviso that, when X, Y, Z independently mean each other 1, 2 or 3 N, 1) the skeleton of subgroup XYZ is not N-CH-N, CH-NN or -NNN and 2) X is not NH when Y and Z are at the same time CH.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004063223A DE102004063223A1 (en) | 2004-12-22 | 2004-12-22 | New quinoline derivatives are ephrin receptor kinase inhibitors useful for the treatment of e.g. blood vessels diseases, hyperproliferations, chronic or acute neurodegenerative diseases, psoriasis, eczema and scleroderma |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052544A1 true AR052544A1 (en) | 2007-03-21 |
Family
ID=36599298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105485A AR052544A1 (en) | 2004-12-22 | 2005-12-22 | DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT |
Country Status (7)
Country | Link |
---|---|
CN (1) | CN101087788A (en) |
AR (1) | AR052544A1 (en) |
DE (1) | DE102004063223A1 (en) |
GT (1) | GT200500381A (en) |
PA (1) | PA8657701A1 (en) |
SV (1) | SV2007002357A (en) |
UY (1) | UY29308A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103382206B (en) * | 2012-05-04 | 2016-09-28 | 上海恒瑞医药有限公司 | Quinoline or quinazoline derivative, its preparation method and in application pharmaceutically |
CN106565823B (en) * | 2016-11-10 | 2020-09-11 | 珠海诺贝尔国际生物医药研究院有限公司 | Eph receptor small molecule inhibitor and preparation method thereof |
CN110577546B (en) * | 2018-06-08 | 2021-09-07 | 江苏威凯尔医药科技有限公司 | VEGFR inhibitor and preparation method and application thereof |
WO2019233458A1 (en) * | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | Vegfr inhibitor, preparation method therefor and use thereof |
CN113150009B (en) * | 2020-01-07 | 2023-05-23 | 爱科诺生物医药(香港)有限公司 | Heterocyclic compound with activity of inhibiting programmed cell necrosis pathway and application thereof |
CN113061142A (en) * | 2020-01-02 | 2021-07-02 | 爱科诺生物医药股份有限公司 | Heterocyclic compounds with programmed cell necrosis pathway inhibition activity and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3919238A (en) * | 1973-06-06 | 1975-11-11 | Morton Norwich Products Inc | 9-(Substituted amino)imidazo(4,5-f) quinolines |
EP0187705A3 (en) * | 1985-01-08 | 1988-05-11 | Norwich Eaton Pharmaceuticals, Inc. | Imidazo(4,5-f)quinolines useful as immunomodulating agents |
EP0597003A1 (en) * | 1991-08-02 | 1994-05-18 | Pfizer Inc. | Quinoline derivatives as immunostimulants |
-
2004
- 2004-12-22 DE DE102004063223A patent/DE102004063223A1/en not_active Ceased
-
2005
- 2005-12-19 CN CNA2005800444603A patent/CN101087788A/en active Pending
- 2005-12-21 GT GT200500381A patent/GT200500381A/en unknown
- 2005-12-22 UY UY29308A patent/UY29308A1/en not_active Application Discontinuation
- 2005-12-22 PA PA20058657701A patent/PA8657701A1/en unknown
- 2005-12-22 SV SV2005002357A patent/SV2007002357A/en not_active Application Discontinuation
- 2005-12-22 AR ARP050105485A patent/AR052544A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
DE102004063223A1 (en) | 2006-07-13 |
PA8657701A1 (en) | 2006-09-08 |
CN101087788A (en) | 2007-12-12 |
UY29308A1 (en) | 2006-06-30 |
GT200500381A (en) | 2006-08-03 |
SV2007002357A (en) | 2007-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38070A (en) | SUBSTITUTE QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | |
PE20180462A1 (en) | TOC MODULATORS AND METHODS OF USING THEM | |
PE20021010A1 (en) | SPIROCYCLIC DERIVATIVES AS PHOSPHODIESTERASE-7 INHIBITORS | |
ECSP088590A (en) | MULTICYCLIC AMINO ACID DERIVATIVES AND THEIR METHODS OF USE | |
AR052544A1 (en) | DERIVATIVE OF QUINOLINA, ITS USE, PREPARATION AND MEDICINAL PRODUCT CONTAINING IT | |
AR078786A1 (en) | CHROMENONE DERIVATIVES | |
AR044078A1 (en) | SUBSTITUTED DIHYDROQUINAZOLINS | |
CO5680439A2 (en) | CYCLOTIOCARBAMATE DERIVATIVES AS PR MODULATORS AND THEIR USE FOR THE TREATMENT OF SKIN DISORDERS | |
DE602006006850D1 (en) | AZABICYCLO (3,1,0) -HEXAN DERIVATIVES SUITABLE AS MODULATORS OF DOPAMINE D3 RECEPTORS | |
UY29469A1 (en) | SULFOXIMINO-MACROCYCLIC COMPOUNDS AND THEIR SALTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH COMPOUNDS, PREPARATION METHODS AND USES OF THE SAME. | |
AR034261A1 (en) | COMPOUNDS DERIVED FROM PIRAZOL [1,5-A] PIRIDINE; PHARMACEUTICAL COMPOSITIONS, ITS USE IN THE MANUFACTURE OF MEDICINES, AND METHODS OF TREATMENT OF DISEASES MEDIATED BY KINASES | |
AR041347A1 (en) | IMIDAZOL DERIVATIVES [1,2-A] PIRAZINAS AS INHIBITORS OF CYCLINE DEPENDENT KINASES | |
AR054035A1 (en) | BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USE OF THE SAME | |
AR050617A1 (en) | SULFONAMID PYRIMIDIN DERIVATIVES AS CHEMIOKIN RECEPTORS MODULATORS | |
AR058703A1 (en) | THYROSINKINASE INHIBITING TRIAZOLOPIRIDAZINS, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THERAPEUTIC AND USES IN THE TREATMENT OF CANCER | |
AR072906A1 (en) | MODIFIED NUCLEOSIDS USEFUL AS ANTIVIRAL | |
AR040806A1 (en) | DERIVATIVES OF PIPERIDI-2-ONA 1.6 DISUSTITUTED, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND TREATMENT METHOD | |
AR085406A1 (en) | N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTERIDINONES | |
AR056511A1 (en) | DERIVATIVES OF 2-AMINOPIRIMIDINES, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DISEASES MEDIATED BY THE HISTAMINE RECEIVER H4 | |
AR048028A1 (en) | 5,6-DIALQUIL-7-AMINO-TRIAZOLOPIRIMIDINAS, PROCEDURES FOR THEIR PREPARATION AND THE USE OF THE SAME TO COMBAT HARMFUL FUNGES, AS WELL AS PRODUCTS CONTAINING THEM | |
AR045388A1 (en) | INHIBITORS OF THE N3-SUBSTITUTED IMIDAZOPIRIDINIC C-KIT | |
UY29070A1 (en) | FUSIONED HETEROCYCLIC ENANTIOMERS AND THEIR USES | |
AR059032A1 (en) | COMBINATION OF TRIAZINE DERIVATIVES AND INSULIN SENSITIZERS | |
BR0209936A (en) | Pharmaceutical combined composition, and use of a cyanoguanidine ikk compound and inhibitor | |
ECSP088257A (en) | AMIDA DERIVATIVES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |